GeneDx (NASDAQ: WGS) has appointed Mark Gardner as President, effective June 15, 2026. Gardner will report to Chief Executive Officer Katherine Stueland and oversee the company's commercial and operations teams.

Gardner most recently served as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics, where he led oncology and genomics operations across precision medicine, rare disease, and advanced diagnostic testing. Before that, he served as Chief Executive Officer of OmniSeq, a precision medicine company later acquired by Labcorp, and held senior roles at Thermo Fisher Scientific and Life Technologies.

"GeneDx has built a powerful foundation and is entering a stage where execution at scale matters more than ever," Stueland said. "Mark brings nearly three decades of experience leading diagnostics, genomics, life sciences and healthcare technology businesses, including at some of the most complex commercial organizations in our industry."

Gardner began his career as a P-3 Orion pilot in the United States Navy, reaching the rank of Lieutenant Commander. He holds an MBA from The Wharton School at the University of Pennsylvania, a master's degree in National Security Studies from Georgetown University, and a bachelor's degree in history from the United States Naval Academy.